Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.
European journal of heart failure(2023)
摘要
The benefits of empagliflozin versus placebo were consistently present across all BMI categories in HFrEF patients. Weight loss was associated with higher risk of all-cause mortality, regardless of treatment group.
更多查看译文
关键词
Body mass index,Empagliflozin,Heart failure,Weight loss
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要